Physician profile
Omar K Hasan
NPI 1154347607
$5,384.61
in general payments reported to CMS, 2019-2025
16 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,009 · 2022: $572 · 2023: $253 · 2024: $130 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.42 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $3,598.41 | 2019-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $484.31 | 2019-2025 | Ingrezza |
| Jazz Pharmaceuticals INC. | $232.57 | 2022-2025 | |
| Avanir Pharmaceuticals, INC. | $203.77 | 2019-2022 | |
| Axsome Therapeutics, INC. | $152.74 | 2024-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $121.48 | 2019 | |
| Lundbeck LLC | $113.59 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $110.08 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $98.88 | 2022-2025 | Invega Sustenna |
| Abbvie INC. | $76.08 | 2022-2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.22 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.02 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.17 | 2024 | Lifevest |
| Corium, LLC | $23.83 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.43 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.